BridgeBio Pharma (BBIO) Cash & Equivalents (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Cash & Equivalents data on file, last reported at $879.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 62.76% year-over-year to $879.9 million; the trailing twelve-month figure through Mar 2026 stood at $879.9 million (up 62.76% YoY), and the FY2025 full-year result was $570.1 million, up 58.46% from the prior year.
• Cash & Equivalents improved to $879.9 million in Q1 2026, from $570.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $879.9 million in Q1 2026 to a low of $266.3 million in Q3 2024.
• A 5-year average of $460.3 million and a median of $408.0 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 167.95% in 2022 and slumped 47.28% in 2024, its largest moves.
• Tracing BBIO's Cash & Equivalents over 5 years: stood at $376.7 million in 2022, then slipped by 0.2% to $375.9 million in 2023, then decreased by 4.3% to $359.8 million in 2024, then soared by 58.46% to $570.1 million in 2025, then soared by 54.33% to $879.9 million in 2026.
• Business Quant data shows BBIO's Cash & Equivalents at $879.9 million in Q1 2026, $570.1 million in Q4 2025, and $283.3 million in Q3 2025.